Fernández JFD, et al. - Researchers tested the performance of Xience Prime everolimus-eluting stent (EES) in consecutive patients (aged 64.8 ± 11.2 years, 77% men and 33% diabetics) with de novo > 24 mm lesions in vessels of 2.25–4 mm in a prospective, multicenter registry performed in 29 tertiary hospitals. Overall participants were 610 patients with 705 long lesions, with lesion length 34.59 ± 11.17 mm, vessel size 2.93 ± 0.41 mm, and stented length 39.83 ± 14.08 mm (1.4 stents per lesion). Extremely good performance of the Xience Prime EES was reported in long lesions, with a very low rate of both major adverse cardiac events (MACE) and stent thrombosis (ST). In this real-world population, the Xience Prime EES offered 99.1% success rate, with MACE and ST rates observed at 1, 12, and 24-months follow-up being 0.3, 2.1, and 5.4% and 0.2, 0.7, and 1.5%, respectively.